Skip to content

Determination of the 90% effective dose of intermittent intravenous phenylephrine for the treatment of spinal anesthesia-induced hypotension in severe pre-eclampsia parturients undergoing cesarean delivery: a sequential allocation dose-finding study

Determination of the 90% effective dose of intermittent intravenous phenylephrine for the treatment of spinal anesthesia-induced hypotension in severe pre-eclampsia parturients undergoing cesarean delivery: a sequential allocation dose-finding study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015805
Enrollment
Unknown
Registered
2018-04-21
Start date
2018-04-23
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean delivery

Interventions

Sponsors

Womens' Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with severe early onset preeclampsia (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 110 mmHg, on = 2 separate occasions; or symptoms of imminent eclampsia (headache, visual disturbance, epigastric pain) with = 3 + proteinuria

Exclusion criteria

Exclusion criteria: We do not recruit patients if they had a contra-indication to spinal anaesthesia; were in active labour; placenta previa or other placental abnormality; had a multiple pregnancy; pulmonary oedema; had a BMI > 40 kg.m2; umbilical cord prolapse; refuse to sign the informed consent

Design outcomes

Primary

MeasureTime frame
successful responses to phenylephrine;Fetal outcomes;

Secondary

MeasureTime frame
The maternal outcomes;

Countries

China

Contacts

Public ContactXiaowei Qian

Womens' Hospital, School of Medicine, Zhejiang University

qianxw@zju.edu.cn+86 15700157161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026